Gareth J Morgan PhD
Research Assistant Professor, Hematology & Medical Oncology
Member, Genome Science Institute
72 E. Concord Street | (617) 358-4750gjmorgan@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Amyloidosis Center
Biography
Gareth Morgan, PhD is a Research Assistant Professor at the Chobanian and Avedisian School of Medicine. His research focuses on the molecular mechanisms of AL amyloidosis with the aim of developing new treatments for this disease.
Other Positions
Education
Biochemistry, PhD, University of Sheffield
Biochemistry, BS, Imperial College London
Publications
Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Singh Bawa P, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. Amyloid. 2025 Jun; 32(2):179-192. PMID: 40134188.
Published on 12/6/2024Morgan GJ, Nau AN, Wong S, Spencer BH, Shen Y, Hua A, Bullard MJ, Sanchorawala V, Prokaeva T. An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis. Amyloid. 2025 Jun; 32(2):129-138. PMID: 39641756.
Published on 11/16/2024Morgan GJ, Yung Z, Spencer BH, Sanchorawala V, Prokaeva T. Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis. Pharmaceuticals (Basel). 2024 Nov 16; 17(11). PMID: 39598451.
Published on 10/28/2024Klimtchuk ES, Prokaeva T, Spencer BH, Wong S, Ghosh S, Urdaneta A, Morgan G, Wales TE, Gursky O. Conformational Differences in the Light Chain Constant Domain of Immunoglobulin G and Free Light Chain May Influence Proteolysis in AL Amyloidosis. J Mol Biol. 2024 Dec 01; 436(23):168837. PMID: 39490919.
Published on 9/15/2024Morgan G, Nau AN, Wong S, Spencer BH, Shen Y, Hua A, Bullard MJ, Sanchorawala V, Prokaeva T. An updated AL-Base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis. bioRxiv. 2024 Sep 15. PMID: 39314448.
Published on 6/21/2024Leach BI, Ferguson JA, Morgan G, Sun X, Kroon G, Oyen D, Dyson HJ, Wright PE. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation. J Mol Biol. 2024 Aug 15; 436(16):168673. PMID: 38909653.
Published on 3/16/2024Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Bawa PS, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. bioRxiv. 2024 Mar 16. PMID: 38558967.
Published on 3/1/2024Wong S, West ME, Morgan GJ. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. Protein Sci. 2024 Mar; 33(3):e4871. PMID: 38100259.
Published on 11/6/2023Gareth J. Morgan. Understanding and Overcoming Biochemical Diversity in AL Amyloidosis. Israel Journal of Chemistry. 2023; e202300128.
Published on 6/6/2023Yan NL, Morgan GJ, Petrassi HM, Wilson IA, Kelly JW. Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis. Curr Opin Chem Biol. 2023 Aug; 75:102319. PMID: 37279624.
Media Mentions
Published on 4/25/2023
Amyloidosis: Beyond Alzheimer’s and Parkinson’s
Published on 4/16/2023
Alzheimer’s-Like Diseases Can Affect the Body — Scientists Are Working to Find Out Why
Published on 4/5/2023
Amyloidosis: Beyond Alzheimer’s and Parkinson’s
View full list of 3 media mentions.